Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically [Yahoo! Finance]
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: Yahoo! Finance
The analysts greatly increased their revenue estimates, suggesting a stark improvement in business fundamentals. Investors have been pretty optimistic on Entrada Therapeutics too, with the stock up 18% to US$16.53 over the past week. We'll be curious to see if these new estimates convince the market to lift the stock price higher still. Following the upgrade, the consensus from four analysts covering Entrada Therapeutics is for revenues of US$175m in 2024, implying a concerning 27% decline in sales compared to the last 12 months. Statutory earnings per share are supposed to nosedive 88% to US$0.37 in the same period. Yet before this consensus update, the analysts had been forecasting revenues of US$144m and losses of US$0.29 per share in 2024. So we can see that this has sparked a pretty clear upgrade to expectations, with higher revenues anticipated to lead to profit sooner than previously forecast. Check out our latest analysis for Entrada Therapeutics Although the analysts ha
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at Oppenheimer Holdings Inc. from $25.00 to $28.00. They now have an "outperform" rating on the stock.MarketBeat
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics Reports Third Quarter 2024 Financial ResultsGlobeNewswire
TRDA
Earnings
- 11/5/24 - Beat
TRDA
Sec Filings
- 11/6/24 - Form 4
- 11/5/24 - Form 10-Q
- 11/5/24 - Form 8-K
- TRDA's page on the SEC website